Futuristics
Long/short equity, biotech, healthcare, small-cap

InterMune: Esbriet And Ascend Will Drive Growth

InterMune (ITMN) has an opportunity to build a market-leading franchise for idiopathic pulmonary fibrosis, or IPF, which represents an attractive market due to its relatively high prevalence, unmet needs, high pricing, and limited competition. The improved sentiment in Europe for Esbriet's launch (also known as pirfenidone) and ASCEND's success probability make InterMune a good stock for long-term growth.

Given the larger homogeneous IPF patient population compared to the CAPACITY studies, I anticipate Esbriet to show a significant statistical improvement (percentage change) in its primary endpoint, for forced vital capacity, or FVC. Esbriet's market is in a growth curve, which bodes very well for its U.S. market potential if the ASCEND data proves to be positive. The ASCEND trial...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details